Chugai Pharmaceutical Co., Ltd. (TYO:4519)
Japan · Delayed Price · Currency is JPY 6,795.00
-83.00 (-1.21%)
Sep 4, 2026, 3:30 PM JST
Chugai Pharmaceutical Income Statement
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,132,851 | 1,077,803 | 997,901 | 974,493 | 1,039,247 | 802,836 |
Other Revenue | 209,958 | 180,138 | 172,710 | 136,874 | 220,699 | 196,923 |
| 1,342,809 | 1,257,941 | 1,170,611 | 1,111,367 | 1,259,946 | 999,759 | |
Revenue Growth | 12.26% | 7.46% | 5.33% | -11.79% | 26.02% | 27.04% |
Cost of Revenue | 384,807 | 363,690 | 339,409 | 413,306 | 476,251 | 338,147 |
Gross Profit | 958,002 | 894,251 | 831,202 | 698,061 | 783,695 | 661,612 |
Selling, General & Admin | 122,758 | 116,461 | 110,098 | 112,580 | 100,760 | 102,416 |
Research & Development | 190,649 | 187,598 | 181,440 | 174,868 | 149,626 | 137,299 |
Other Operating Expenses | -520 | -8,641 | -2,339 | -28,561 | - | - |
Operating Expenses | 312,887 | 295,418 | 289,199 | 258,887 | 250,386 | 239,715 |
Operating Income | 645,115 | 598,833 | 542,003 | 439,174 | 533,309 | 421,897 |
Interest Expense | -153 | -207 | 5 | -27 | -61 | -48 |
Interest & Investment Income | 5,131 | - | 1,027 | 4,674 | 52 | - |
Other Non Operating Income (Expenses) | 5,104 | -820 | -1 | - | -2,134 | -2,464 |
Pretax Income | 655,197 | 597,806 | 543,034 | 443,821 | 531,166 | 419,385 |
Income Tax Expense | 183,825 | 163,794 | 155,717 | 118,349 | 156,737 | 116,390 |
Earnings From Continuing Operations | 471,372 | 434,012 | 387,317 | 325,472 | 374,429 | 302,995 |
Net Income | 471,372 | 434,012 | 387,317 | 325,472 | 374,429 | 302,995 |
Net Income to Common | 471,372 | 434,012 | 387,317 | 325,472 | 374,429 | 302,995 |
Net Income Growth | 19.20% | 12.06% | 19.00% | -13.08% | 23.58% | 41.10% |
Shares Outstanding (Basic) | 1,646 | 1,646 | 1,645 | 1,645 | 1,645 | 1,644 |
Shares Outstanding (Diluted) | 1,646 | 1,646 | 1,646 | 1,645 | 1,645 | 1,645 |
Shares Change | 0.00% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
EPS (Basic) | 286.43 | 263.73 | 235.39 | 197.83 | 227.64 | 184.29 |
EPS (Diluted) | 286.42 | 263.72 | 235.36 | 197.80 | 227.57 | 184.17 |
EPS Growth | 19.20% | 12.05% | 18.99% | -13.08% | 23.57% | 41.09% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 400,722 | 310,007 | 397,185 | 337,977 | 181,487 | 213,657 |
Free Cash Flow Per Share | 243.49 | 188.37 | 241.36 | 205.40 | 110.30 | 129.87 |
Dividend Per Share | 138.000 | 122.000 | 98.000 | 80.000 | 78.000 | 76.000 |
Dividend Growth | 28.97% | 24.49% | 22.50% | 2.56% | 2.63% | 38.18% |
Gross Margin | 71.34% | 71.09% | 71.01% | 62.81% | 62.20% | 66.18% |
Operating Margin | 48.04% | 47.60% | 46.30% | 39.52% | 42.33% | 42.20% |
Profit Margin | 35.10% | 34.50% | 33.09% | 29.29% | 29.72% | 30.31% |
Free Cash Flow Margin | 29.84% | 24.64% | 33.93% | 30.41% | 14.40% | 21.37% |
EBITDA | 678,050 | 631,368 | 573,668 | 470,914 | 564,743 | 452,765 |
EBITDA Margin | 50.50% | 50.19% | 49.01% | 42.37% | 44.82% | 45.29% |
D&A For EBITDA | 32,935 | 32,535 | 31,665 | 31,740 | 31,434 | 30,868 |
EBIT | 645,115 | 598,833 | 542,003 | 439,174 | 533,309 | 421,897 |
EBIT Margin | 48.04% | 47.60% | 46.30% | 39.52% | 42.33% | 42.20% |
Effective Tax Rate | 28.06% | 27.40% | 28.68% | 26.67% | 29.51% | 27.75% |